Conditionally MYC: insights from novel transgenic models.
MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.
Arvanitis
Constadina
C
Departments of Medicine and Pathology, Division of Oncology, School of Medicine, Stanford University, CCSR 1105B, 269 Campus Drive, Stanford, CA 94305-5151, USA.
Felsher
Dean W
DW
D000818:Animals; D004195:Disease Models, Animal; D016259:Genes, myc / Q000235:genetics*; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic